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e Must Prevent
isease, Not Predict Events*
llan D. Sniderman, MD
ontreal, Quebec, Canada
here are large lessons to learn from the Cardiovascular Risk
tudy in Young Finns, published in this issue of the Journal (1).
wo reiterate what we already knew but have largely ignored—
rst, whether we are paying attention or not, atherosclerosis is
ell underway by the third and fourth decades of our lives and,
econd, this disease is directly traceable to the atherogenic
mbalance in the plasma lipoproteins that is identifiable by
uberty. As important as these lessons are, Juonala et al. (1),
reak much fresh ground.
See page 293
They found that the plasma apolipoprotein (apo) B and the
poB/apoA-I ratio at age 12 to 18 years were directly related to
arotid artery intima-media thickness (IMT) at age 24 to 39
ears, whereas apoA-I was indirectly related to carotid IMT.
oreover, these relations were not altered when adult levels of
he apolipoproteins and non-lipid risk factors were taken into
ccount. In addition, the same relations were noted, although
n samples from an even earlier age, between the levels of the
poB, apoB/apoA-I ratio and impaired flow-mediated vasodi-
atation (FMD). Also of interest was the lack of any significant
ender interaction between the association of the apolipopro-
eins and either carotid IMT or FMD.
That the plasma lipoproteins matter in atherogenesis and
hat atherogenesis starts early should be easy for all to
ccept. The challenge lies in what follows. Juonala et al. (1)
emonstrate convincingly that apoB is superior to both
ow-density lipoprotein (LDL) cholesterol and non–high-
ensity lipoprotein (HDL) cholesterol as an estimate of the
therogenic lipoproteins, that apoA-I is superior to HDL
holesterol as a marker of the antiatherogenic lipoproteins, and
hat the apoB/apoA-I ratio was significantly better than either
he LDL/HDL cholesterol or the non–HDL/HDL choles-
erol ratio as overall estimates of the lipoprotein-related vascu-
ar disease (1). Not only were the standardized beta coefficients
f the apolipoproteins substantially greater than their choles-
Editorials published in the Journal of the American College of Cardiology reflect the views
f the authors and do not necessarily represent the views of JACC or the American College
f Cardiology.2
From the Mike Rosenbloom Laboratory for Cardiovascular Research, McGill
niversity, Montreal, Quebec, Canada.erol counterparts, but significant differences in favor of the
poB/apoA-I ratio were also evident by the c-statistic.
Perhaps no other issue in lipidology has been as contentious
s the debate as to whether cholesterol or apolipoproteins are
etter markers of risk. All major guideline groups had already
mbraced cholesterol, and prior commitment and the per-
eived need for continuity are potent arguments for the status
uo. However as the number of studies comparing apoB with
DL cholesterol has mounted, the comparison has become
ne-sided. Except in the oldest subjects where LDL by any
easure is not predictive (2), in all other groups, whether those
ith symptomatic disease or those without, in men or women,
hose receiving therapy or those not treated, apoB has come
ut on top against LDL cholesterol (Online Appendix, sup-
lementary references 1 to 23).
Understandably, it is not easy for most clinicians to fully
ppreciate just how clear the difference in predictive power is.
azard ratios, c-statistics, and p values do not translate into
imple, intuitively transparent, quantitative comparisons. In
his instance, a picture is worth more than any number of
ords, and perhaps the best comes from Framingham. Figure
compares the predictive power of LDL particle number
LDL P) versus LDL cholesterol in the Framingham Off-
pring Study (3). Apolipoprotein B measures all the athero-
enic particles, of which more than 90% are LDL particles (4).
he apoB and LDL P are therefore equivalent markers. Figure
demonstrates that when both LDL cholesterol and LDL P
re high, so is risk, and when both are low, so is risk. The battle
s decided when they differ. When LDL P is high but LDL
holesterol is low, risk is high. When LDL P is high but LDL
holesterol is low, risk is high. The outcome could not be
learer: it is the number of atherogenic particles rather than the
holesterol they contain that we should measure.
On the basis of our knowledge of the biology of atheroscle-
osis, this should not be surprising. Atherosclerosis is what
appens after apoB lipoprotein particles are trapped within the
rterial wall. Moreover, the number of apoB particles in plasma
etermines the likelihood of an apoB particle entering and
eing trapped within the arterial wall (4). Take away the apoB
articles and you take away atherosclerosis. Conversely, be-
ause LDL particles contain variable amounts of cholesterol,
DL cholesterol might seriously underestimate or overesti-
ate apoB particle number leading to either under-treatment
r to over-treatment and therefore to failure to prevent events
hat were preventable or to excessive cost and risk with therapy
hat was not necessary. Although much attention has been paid
s to whether smaller cholesterol-depleted LDL particles are
ore—or less—atherogenic than their larger cholesterol-
nriched counterparts, the majority of recent studies indicate
hat all LDL particles are atherogenic and that if one is worse
han the other, it is a distinction without a difference (5–7).
Non-HDL cholesterol is closer to apoB and LDL P in
redictive power. Indeed, they finish in a statistical tie in
everal studies (Online Appendix, supplementary references
4–28), but apoB winds up ahead in even more (Online
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July 22, 2008:300–1 Editorial Commentppendix, supplementary references 29–38) including the
resent study (1). Moreover, statin therapy lowers LDL
holesterol and non-HDL cholesterol more than apoB or
DL P (8). These are amongst the reasons that the
merican Diabetes Association and the American College
f Cardiology have issued a joint consensus statement
ecommending that apoB be the final test of the adequacy of
DL-lowering therapy (9).
In contrast, the outcome of the contest between apoA-I
ersus HDL cholesterol remains unclear. Some studies such
s the AMORIS (Apolipoprotein-Related Mortality Risk)
tudy favor apoA-I (10), whereas others, such as the Framing-
am Offspring Study, strongly favor HDL cholesterol (11).
ere more information is required. Even worse, although we
now that HDL matters, the fact is that we do not know why.
o its benefits relate to removal of cholesterol from the artery?
nd even if they do, how does the plasma level of HDL
holesterol relate to that? Or is HDL “good” because it is
nti-inflammatory? And if so, which component(s) count most?
What then are the large lessons from this study by Juonala
t al. (1)? First, although the plasma lipoproteins are only risk
actors for clinical events, they are prime causes of disease
ithin the arteries. Second, transformation of a stable silent
rterial lesion into an unstable one that produces a clinical
vent is a complex and unpredictable process. We know what
auses disease within our arteries but can only guess at precisely
hat precipitates clinical events. It follows that prevention of
oronary disease would be much simpler and much more
ffective if we focused on preventing disease developing within
Figure 1 Cardiovascular Risk: LDL P Versus LDL C
The outcome of 4 groups are depicted: high low-density lipoprotein (LDL) parti-
cle number (P) and high LDL cholesterol (C); low LDL P and low LDL C; high
LDL P but low LDL C; and low LDL P but high LDL C. Adapted, with permission,
from the Framingham Offspring Study (3).ur arteries rather than trying to predict who is just about to pecome a victim and then trying frantically, at what might be
ust 1 min before their final midnight, to rescue them (12). The
igh-risk approach to prevention is often too high-risk for the
atient and too late for his or her arteries. The bottom line is
hat, just as we need to revise how we measure the lipoprotein-
elated risk of vascular disease, we also need to revise when it is
ppropriate to correct the proatherogenic imbalance of the
poB and apoA-I lipoproteins to prevent the initiation and
rogression of advanced arterial disease. If we prevent the
isease, we will prevent the events.
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